*Refresh the page if the below document does not appear.
A report submitted to NPPA by Indian Pharmaceutical Alliance (IPA) said that the company was “following the practices according to the UCPMP guidelines” and found nothing incorrect.
The state is experiencing a shortage of life saving drugs as the manufacturing units stopped the production. As per the reports, retailers are also asking high prices for drugs that are available and even NPPA is unable to manage the prices.
CERVIVAC, is all set to be made available towards the end of this year and will cost around ₹ 200 – 400 a shot. It is indicated to be effective against at least four variants of HPV (Human Papilloma Virus).
The lucrative US market has been experiencing flat for the past 12 months resulting in double digit negative return for the stocks. In the past few years, problems like constant pricing pressure and increasing regulatory scrutiny are some of the reasons for low returns.
Zydus acquired rights from Pharmacosmos to market MonoFerric (iron isomaltoside) Injections in India and Nepal. Since its launch, 28 million doses of the drug have been administered in about 30 countries including the USA.
The company stated that the drug is already approved for treating conditions such as psoriasis and arthritis, and now has shown positive results in trial patients suffering from hidradenitis suppurativa.
SOTYKTU, is a first of its kind drug for the
treatment of plaque psoriasis. It is an oral pill
which makes it more convenient to administer
as compared to its counterparts AbbVie’s Humira
and Amgen’s Enbrel, which are injectables.
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website